ARTV
ARTV clinical trials: Artiva Biotherapeutics, Inc.
Every trial on ClinicalTrials.gov where Artiva Biotherapeutics, Inc. is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 7
- Trials linked
- 4
- As lead sponsor
- 3
- As collaborator
- 0
- Primary completions as lead sponsor, next 90 days
ARTV on the catalyst calendar · ARTV registry changes
- Primary completion Jan 2028Sponsor estimatePhase 2NCT06991114AlloNK®, an Allogeneic Non-genetically Modified, Cord Blood-derived NK Cell Therapy, in Combination With Rituximab, Studied in Relapsing...Artiva Biotherapeutics, Inc. · Refractory Rheumatoid Arthritis (RA)RecruitingARTVLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 6, 2025ActualPhase 1/Phase 2NCT04673617AB-101 as Monotherapy and With Immunotherapy in Patients With Relapsed/Refractory B-Cell Non-Hodgkin LymphomaArtiva Biotherapeutics, Inc. · Non Hodgkin LymphomaCompletedARTVLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 2027Sponsor estimatePhase 1NCT06265220AB-101 in Combination With B-Cell Depleting mAb in Patients Who Failed Treatment for Class III or IV Lupus Nephritis or Other Forms of...Artiva Biotherapeutics, Inc. · Lupus Nephritis - WHO Class IIIActive, not recruitingARTVLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 2027Sponsor estimatePhase 1/Phase 2NCT05678205A Clinical Trial of the Safety and Anti-Tumor Activity of AB-201 in Subjects With Advanced HER2+ Solid TumorsArtiva Biotherapeutics, Inc. · Breast CancerWithdrawnARTVLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 2027Sponsor estimatePhase 1NCT06699771Phase 1 to Investigate the Safety, Tolerability, and Efficacy of GCC2005 in Patients With R/R NK and T-cell MalignanciesGC Cell Corporation · Lymphoma, T-CellRecruitingARTVCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 7, 2024ActualPhase 2NCT05883449Phase 2 Study of AFM13 in Combination With AB-101 in Subjects With R/R HL and CD30+ PTCLAffimed GmbH · Relapsed or Refractory Hodgkin LymphomaTerminatedARTVCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 2027Sponsor estimatePhase 1NCT06581562Open-label Single-Center Study to Evaluate the Safety and Efficacy of Combining Rituximab and AB-101 in B-cell Associated Autoimmune...IRIS Research and Development, LLC · Rheumatoid ArthritisRecruitingARTVCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 7 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScanner